HOME >> MEDICINE >> NEWS
Exploring better ways to determine when to change the course of treatment

Counting circulating tumor cells before and after the start of treatment for patients with metastatic colorectal cancer could help doctors determine when or if a change in treatment should be made. The results of a large, multicenter, international study laying the groundwork for such decisions were presented today at the Annual Meeting of the American Society of Clinical Oncology. The study showed the number of circulating tumor cells, or CTC, is a significant predictor of survival and cancer progression.

Few studies have examined the relationship of CTC and a patient's prognosis in cancer. This is an important area of research in metastatic colorectal cancer because there are little data to help physicians chose which treatment is best for which patients or to determine when a change in treatment is warranted.

"If we had a way to know early on that a tumor isn't responding to a particular drug, we could switch to a different treatment before growth of the cancer is seen on a CAT scan," said Neal J. Meropol, director of the gastrointestinal cancer program at Fox Chase Cancer Center and lead investigator of the study. "If we could determine that the tumor was destined to grow after a few weeks of treatment, we'd be able alter course even before the first scan."

For this study, Meropol and his colleagues examined the association between the circulating tumor cell number and progression-free and overall survival for 430 adult patients with metastatic colorectal cancer.

The number of CTC was measured at baseline, one month, and several other points after the start of treatment. CTC were isolated and counted by an immunomagnetic cell separation technique, an FDA-approved technology developed by Immunicon Corporation (Nasdaq-Global Market: IMMC}. CT scans were obtained in usual practiceat baseline and every 6-12 weeks after starting treatment.

Having 3 or more CTC (per 7.5 mL of blood) was defined as "unfavo
'"/>

Contact: Karen Mallet
karen.mallet@fccc.edu
215-728-9751
Fox Chase Cancer Center
3-Jun-2007


Page: 1 2

Related medicine news :

1. Exploring the molecular origin of blood clot flexibility
2. Exploring the potential of cholesterol-lowering drugs for patients with systemic sclerosis
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
5. Warfarin better than aspirin at stroke prevention in elderly people with atrial fibrillation
6. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
7. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
8. Holograms make for better vision tests
9. Parents of chronically ill kids are helped by better access to federal and employer leave
10. Diabetes professionals join forces to identify gaps in diabetes care and better self care
11. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Exploring better ways determine when change the course treatment

(Date:3/6/2015)... Protein identification is increasingly being ... science research including drug discovery, diagnostics, immunology and ... was valued at $1,569.00 million in 2014 and ... 10.63% to reach $2,600.28 million in 2019. , ... protein based on protein size, shape, sequence and ...
(Date:3/6/2015)... As healthcare providers create one ... from disparate systems, they are using OnBase by ... efficiency. Enterprise content management (ECM) solutions ... IT solutions, including electronic medical records (EMR), enterprise ... , The following organizations have recently integrated ...
(Date:3/6/2015)... March 06, 2015 Saving Moses, a ... the world is traveling to Angola, Africa March 7-14 ... their malnutrition program. , This will be the organizations ... Angola, demonstrating their commitment to the region’s population by ... team will engage with the mothers and babies of ...
(Date:3/6/2015)... 06, 2015 Follow us on ... pharmacokinetics of a drug refers to testing of absorption, ... an organism. When toxicity studies are clubbed together with ... ADME/Tox. Increasing focus on lowering costs and time during ... worldwide. The traditional drug development model uses toxicity and ...
(Date:3/6/2015)... March 06, 2015 “On Tap” takes the ... the grand stage, to the silver screen and to modern ... precision toe-tapping numbers and their famous eye-high kicks! Producers, directors ... rich history of tap dancing in this robust show, showcasing ... of the United States. , “On Tap” is proud ...
Breaking Medicine News(10 mins):Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 2Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 3Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 2Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 3Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2
(Date:3/6/2015)... , March 6, 2015  Palatin Technologies, Inc. (NYSE MKT: ... 27 th Annual ROTH Conference on Wednesday, March 11, ... held at the Ritz Carlton Laguna Niguel in ... Spana , Ph.D., President and Chief Executive Officer of Palatin ... programs. About Palatin Technologies, Inc. ...
(Date:3/6/2015)... , March 6, 2015   Hospira, Inc. ... Food and Drug Administration (FDA) on today,s FDA approval of ... . This is a watershed moment for improving patient access ... leading global provider of biosimilars, Hospira has seen first-hand the ... a proud participant in these early stages of the development ...
(Date:3/6/2015)... March 6, 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the ... diseases and cancer, today announced that James A. ... present a corporate overview at the 27th Annual ROTH ... time.  Aethlon was previously scheduled to present at 5:30 ... will be held at The Ritz-Carlton Hotel in ...
Breaking Medicine Technology:Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2
Cached News: